Navigation Links
First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

efits (e.g., improved patient outcomes) of therapies. Previous economic models made assumptions regarding the impact of IFN-(beta) on treatment effects (e.g., constant treatment effects over time) because of data limitations, which also made it difficult to examine the impact NAbs have on cost-effectiveness, as they may inhibit the effectiveness of IFN-(beta) treatment. The model used in the present analysis assumed that NAbs would impact the probability of relapse only after the second year of continuous interferon treatment and therefore potentially negatively affect treatment cost and outcomes for therapies susceptible to the development of NAbs.

"The development of NAbs have been shown to reduce the efficacy of IFN-(beta) therapies on magnetic resonance imaging (MRI) outcomes, relapse rate and disability progression, which in turn may affect the cost and outcomes associated with these therapies," Johnson said. "Although the results of this study provide decision makers with relevant data to evaluate the cost-effectiveness of immunomodulatory treatments versus symptom management in treating RRMS, it is important to consider the results in context, given that head-to-head randomized clinical trials comparing the immunomodulatory therapies are necessary to validate the projections from the pharmacoeconomic analyses."

About the Study

A literature-based Markov model was developed to estimate the economic outcomes of five treatment strategies: symptom management (e.g., physical therapy/exercise and pharmacological treatment) alone and symptom management combined with COPAXONE(R) (glatiramer acetate injection), IM-IFN(beta)1-a (Avonex(R)), SC-IFN(beta)1-a (Rebif(R)), or SC-IFN(beta)1-b (Betaseron(R)) in patients diagnosed with RRMS. This is the first economic model in MS to incorporate long-term data on treatment effects, account for differences among clinical trial designs of the immunomodulatory therapies and present the results in terms of cost-
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:11/21/2014)... UNION CITY, Calif. , Nov. 21, 2014 /PRNewswire/ ... products company manufacturing point-of-care instruments and consumables for the ... lab services to the veterinary and research markets in ... the completion of a stock purchase agreement to acquire ... United Kingdom based distribution organization. The ...
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 2Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 3Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 4Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... has been a historical time for Angeldress.co.uk, an excellent wedding ... some renowned review websites. Recently, the company has added to ... of wonderful sexy wedding dresses to its website. At the ... to an 80% discount on any order over GBP 149. ... dress at Angeldress.co.uk, which has garnered a hard core of ...
(Date:11/22/2014)... The Sports Conflict Institute is pleased to ... team of conflict resolution professionals. Baroff comes to SCI as ... has over 30 years experience as an arbitrator, educator, and ... to connect with SCI and bring my conflict resolution skills ... with a complete sports focus,” says Baroff. , “Roy has ...
(Date:11/22/2014)... Washington, DC (PRWEB) November 22, 2014 ... its monthly Tech Report , which features the ... Sofastaii, a technology expert and reporter for NewsWatch, conducted ... can easily improve the flavor of your water. , ... are everywhere. It’s important that everything is done to ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... cent OBC quota in Central educational institutions, Union Health ... was a media creation // and that the ... ,'The resistance was all by the media,' Ramadoss ... had supported the government proposal, he said 'This is ...
... more likely to suffer from cancer and die from it, ... at Israel's //Haifa University suspect that cancers are most likely ... II. ,The researchers looked at the incidence and ... European origin - comparing those who emigrated from Europe before ...
... trying to reattach the foot of a four-year-old boy. The boy ... father // riding over him on a lawn mover. ... a lawn mower when the boy came up unexpectedly behind him. ... into reverse and accidentally ran over the boy's leg. It was ...
... women to donate their eggs for research as they ... // which they say would hopefully find new treatments ... disease. ,They want to extract embryonic stem ... patients with diabetes or neurodegenerative disease, according to Nature ...
... antibiotics for three days rather than the usual concept of ... of common pneumonia // . ,According to researchers ... antibiotic-resistant bacteria, ,Lead researcher Dr. Jan M Prins, ... in Amsterdam said,’The question is how long you should treat ...
... conducted by Dr Taraneh Dean of the University of Portsmouth and ... restricted // in their food intakes because their parents ... team found that found that 54 per cent of a sample ... their parents were convinced that such food items initiated ...
Cached Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2
... Parachute Tissue Anchor allows one step fixation of ... for arthroscopic knotless rotator cuff repair in one ... an outside thread diameter of 5 mm and ... FiberWire suspension sutures securely hold a thin, bioabsorbable ...
... The Bio-SutureTak is a 3 mm bioabsorbable ... ideal for soft tissue attachment to bone in ... small anchor profile with high pull-out strength is ... molded into the body of the anchor and ...
TigerStick is a white #2 FiberStick with black stripes and a stiffened, 12 inch, waxed end. It is especially useful when motion determination and alternating colored sutures are required in the arthr...
... MMS soon offers the Flowmaster. It is ... everyday flow studies, where ease of use, simplicity ... wireless uroflowmeter which makes it now very easy ... the flowmaster anywhere you want and data will ...
Medicine Products: